MX2023007817A - Polipéptidos de cd8, composiciones y métodos de uso de estos. - Google Patents
Polipéptidos de cd8, composiciones y métodos de uso de estos.Info
- Publication number
- MX2023007817A MX2023007817A MX2023007817A MX2023007817A MX2023007817A MX 2023007817 A MX2023007817 A MX 2023007817A MX 2023007817 A MX2023007817 A MX 2023007817A MX 2023007817 A MX2023007817 A MX 2023007817A MX 2023007817 A MX2023007817 A MX 2023007817A
- Authority
- MX
- Mexico
- Prior art keywords
- polypeptides
- methods
- compositions
- present disclosure
- tcr
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 108091008874 T cell receptors Proteins 0.000 abstract 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 238000002659 cell therapy Methods 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K40/427—PRAME
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/55—Vectors comprising as targeting moiety peptide derived from defined protein from bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063132824P | 2020-12-31 | 2020-12-31 | |
| DE102021100038.6A DE102021100038A1 (de) | 2020-12-31 | 2021-01-04 | Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung |
| US202163247775P | 2021-09-23 | 2021-09-23 | |
| PCT/US2021/065367 WO2022147029A2 (en) | 2020-12-31 | 2021-12-28 | Cd8 polypeptides, compositions, and methods of using thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023007817A true MX2023007817A (es) | 2023-09-13 |
Family
ID=80445995
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023007817A MX2023007817A (es) | 2020-12-31 | 2021-12-28 | Polipéptidos de cd8, composiciones y métodos de uso de estos. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20250146019A1 (https=) |
| EP (1) | EP4271481A2 (https=) |
| JP (1) | JP2024502034A (https=) |
| KR (1) | KR20230135589A (https=) |
| AU (1) | AU2021411495A1 (https=) |
| CA (1) | CA3203118A1 (https=) |
| CL (1) | CL2023001939A1 (https=) |
| CO (1) | CO2023008645A2 (https=) |
| CR (1) | CR20230295A (https=) |
| IL (1) | IL304157A (https=) |
| MX (1) | MX2023007817A (https=) |
| PE (1) | PE20250846A1 (https=) |
| TW (1) | TW202241938A (https=) |
| WO (1) | WO2022147029A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116715750B (zh) * | 2023-03-14 | 2024-04-12 | 新景智源生物科技(苏州)有限公司 | 特异性识别prame抗原的tcr及其与cd8共表达来重定向cd4 t细胞 |
| WO2025096649A1 (en) * | 2023-11-01 | 2025-05-08 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0633943A4 (en) | 1992-04-03 | 1997-05-02 | Alexander T Young | GENTHERAPY USING TARGETED VIRAL VECTORS. |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| US9840695B2 (en) | 2009-04-28 | 2017-12-12 | Agriculture Victoria Services Pty Ltd | Plant technology |
| GB201004551D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| GB201423361D0 (en) | 2014-12-30 | 2015-02-11 | Immatics Biotechnologies Gmbh | Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides |
| GB201504502D0 (en) | 2015-03-17 | 2015-04-29 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers |
| GB201505305D0 (en) | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| GB201505585D0 (en) | 2015-03-31 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers |
| GB201507719D0 (en) | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
| GB201510771D0 (en) | 2015-06-19 | 2015-08-05 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer |
| GB201511191D0 (en) | 2015-06-25 | 2015-08-12 | Immatics Biotechnologies Gmbh | T-cell epitopes for the immunotherapy of myeloma |
| GB201511546D0 (en) | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| GB201511792D0 (en) | 2015-07-06 | 2015-08-19 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers |
| MY189596A (en) | 2015-07-15 | 2022-02-18 | Immatics Biotechnologies Gmbh | A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers |
| GB201513921D0 (en) | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| US10335471B2 (en) | 2015-08-28 | 2019-07-02 | Immatics Biotechnologies Gmbh | Method for treating cancer with activated T cells |
| GB201517538D0 (en) | 2015-10-05 | 2015-11-18 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
| HK1258444A1 (zh) | 2015-10-09 | 2019-11-15 | Immatics Biotechnologies Gmbh | 抗wt1/hla特异性抗体 |
| GB201521746D0 (en) | 2015-12-10 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers |
| GB201521894D0 (en) | 2015-12-11 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against various cancers |
| GB201522667D0 (en) | 2015-12-22 | 2016-02-03 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers |
| GB201602918D0 (en) | 2016-02-19 | 2016-04-06 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers |
| GB201603568D0 (en) | 2016-03-01 | 2016-04-13 | Immatics Biotechnologies Gmbh | Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer |
| GB201603987D0 (en) | 2016-03-08 | 2016-04-20 | Immatics Biotechnologies Gmbh | Uterine cancer treatments |
| GB201604494D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers |
| GB201604492D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers |
| GB201604458D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| NZ746387A (en) | 2016-03-16 | 2022-08-26 | Immatics Biotechnologies Gmbh | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers |
| CN116731156A (zh) | 2016-03-16 | 2023-09-12 | 伊玛提克斯生物技术有限公司 | 用于癌症免疫治疗的转染t细胞和t细胞受体 |
| ZA201900664B (en) | 2016-08-17 | 2021-09-29 | Paul Ehrlich Strasse 15 Tuebingen 72076 Germany | T cell receptors and immune therapy using the same |
| DE102016115246C5 (de) | 2016-08-17 | 2018-12-20 | Immatics Biotechnologies Gmbh | Neue t-zellrezeptoren und deren verwendung in immuntherapie |
| CN109996868A (zh) * | 2016-09-23 | 2019-07-09 | 弗雷德哈钦森癌症研究中心 | 特异性用于次要组织相容性(h)抗原ha-1的tcr及其用途 |
| EP3300863B1 (en) | 2016-09-28 | 2020-06-17 | Braun GmbH | Electric shaver |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| KR20240007775A (ko) | 2016-12-08 | 2024-01-16 | 이매틱스 바이오테크놀로지스 게엠베하 | T 세포 수용체 및 이를 사용하는 면역 요법 |
| DE102016123859B3 (de) | 2016-12-08 | 2018-03-01 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
| DE102016123847B3 (de) | 2016-12-08 | 2018-04-05 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
| DE102017106305A1 (de) | 2017-03-23 | 2018-09-27 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten |
| US11236145B2 (en) | 2017-03-23 | 2022-02-01 | Immatics Biotechnologies Gmbh | T cell receptors and immune therapy using the same against PRAME positive cancers |
| WO2018189148A1 (en) | 2017-04-10 | 2018-10-18 | Immatics Biotechnologies Gmbh | Peptides and combination thereof for use in the immunotherapy against cancers |
| EA201992416A1 (ru) | 2017-04-10 | 2020-02-25 | Имматикс Байотекнолоджиз Гмбх | Пептиды и комбинации пептидов для применения в иммунотерапии лейкозов и других видов рака |
| DE102017114737A1 (de) | 2017-06-30 | 2019-01-03 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
| LT3428194T (lt) | 2017-07-14 | 2021-12-10 | Immatics Biotechnologies Gmbh | Pagerinta dvejopo savitumo polipeptido molekulė |
| DE102017212608B4 (de) | 2017-07-21 | 2023-11-16 | Ford Global Technologies, Llc | Radnaben-Einheit mit Wärmedämmbeschichtung zur Reduzierung der thermischen Belastung eines Radlagers |
| KR20250052472A (ko) | 2017-11-06 | 2025-04-18 | 이매틱스 바이오테크놀로지스 게엠베하 | 신규 조작된 t 세포 수용체 및 이를 사용하는 면역 요법 |
| DE102017127984B4 (de) | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen |
| DE102018100967B4 (de) | 2018-01-17 | 2019-08-14 | Immatics US, Inc. | Verfahren zur feststellung der wirksamkeit von viralen vektoren |
| BR112020016176A2 (pt) | 2018-02-09 | 2022-02-22 | Immatics Us Inc | Métodos de transdução de uma célula t, célula t transduzida geneticamente, composição farmacêutica, métodos de preparação de uma população de células t e uso da célula t |
| DE102018107224A1 (de) | 2018-02-21 | 2019-08-22 | Immatics Biotechnologies Gmbh | Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| CA3097396A1 (en) * | 2018-04-19 | 2019-10-24 | Baylor College Of Medicine | Reprogramming cd4 t cells into cytotoxic cd8 cells by forced expression of cd8ab and class 1 restricted t cell receptors |
| DE102018122546B3 (de) | 2018-09-14 | 2019-12-05 | Immatics Biotechnologies Gmbh | Verfahren zum Hochdurchsatz-Peptid-MHC-Affinitätsscreening für TCR-Liganden |
| WO2020185796A1 (en) * | 2019-03-11 | 2020-09-17 | Fred Hutchinson Cancer Research Center | High avidity wt1 t cell receptors and uses thereof |
| WO2020243134A1 (en) * | 2019-05-27 | 2020-12-03 | Immatics US, Inc. | Viral vectors and their use in adoptive cellular therapy |
| US12011459B2 (en) | 2019-06-06 | 2024-06-18 | Immatics US, Inc. | Methods for manufacturing T cells by direct sorting and compositions thereof |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
-
2021
- 2021-12-28 TW TW110149054A patent/TW202241938A/zh unknown
- 2021-12-28 MX MX2023007817A patent/MX2023007817A/es unknown
- 2021-12-28 CA CA3203118A patent/CA3203118A1/en active Pending
- 2021-12-28 EP EP21857024.0A patent/EP4271481A2/en active Pending
- 2021-12-28 AU AU2021411495A patent/AU2021411495A1/en active Pending
- 2021-12-28 CR CR20230295A patent/CR20230295A/es unknown
- 2021-12-28 KR KR1020237025427A patent/KR20230135589A/ko active Pending
- 2021-12-28 JP JP2023539975A patent/JP2024502034A/ja active Pending
- 2021-12-28 WO PCT/US2021/065367 patent/WO2022147029A2/en not_active Ceased
- 2021-12-28 PE PE2023001975A patent/PE20250846A1/es unknown
-
2023
- 2023-06-29 CO CONC2023/0008645A patent/CO2023008645A2/es unknown
- 2023-06-29 IL IL304157A patent/IL304157A/en unknown
- 2023-06-29 CL CL2023001939A patent/CL2023001939A1/es unknown
-
2025
- 2025-01-14 US US19/020,283 patent/US20250146019A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3203118A1 (en) | 2022-07-07 |
| CR20230295A (es) | 2023-07-27 |
| EP4271481A2 (en) | 2023-11-08 |
| US20250146019A1 (en) | 2025-05-08 |
| PE20250846A1 (es) | 2025-03-21 |
| WO2022147029A2 (en) | 2022-07-07 |
| CL2023001939A1 (es) | 2023-12-15 |
| TW202241938A (zh) | 2022-11-01 |
| KR20230135589A (ko) | 2023-09-25 |
| IL304157A (en) | 2023-09-01 |
| JP2024502034A (ja) | 2024-01-17 |
| CO2023008645A2 (es) | 2023-09-18 |
| WO2022147029A3 (en) | 2022-09-09 |
| AU2021411495A1 (en) | 2023-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024013181A (es) | Interleucina 15 (il-15) unida a membrana, polipéptidos del cúmulo de diferenciación 8 (cd8), células, composiciones y métodos de uso de los mismos | |
| WO2022115641A3 (en) | Antigen specific t cells and methods of making and using same | |
| MX2023007817A (es) | Polipéptidos de cd8, composiciones y métodos de uso de estos. | |
| MX2023006878A (es) | Composiciones y métodos para reducir el mhc de clase ii en una célula. | |
| PH12021550307A1 (en) | T Cell Receptor Constructs And Uses Thereof | |
| MX2022012409A (es) | Celulas que presentan antigeno artificial manipulado por ingenieria para expansion linfocitica infiltrante de tumores. | |
| EP4427810A3 (en) | Methods for treatment using adoptive cell therapy | |
| MX2020006689A (es) | Composiciones de vcar y metodos de uso. | |
| MX2023007466A (es) | Composiciones y métodos para reducir los hla-a en una célula. | |
| WO2020181240A8 (en) | Identification of neoantigens with mhc class ii model | |
| Terrén et al. | Modulating NK cell metabolism for cancer immunotherapy | |
| MX2012004881A (es) | Metodos para reprogramar células y sus usos. | |
| MX2022013599A (es) | Métodos para el cultivo de células. | |
| WO2019067951A3 (en) | Cd1d and tcr-nkt cells | |
| GB2623654A8 (en) | Il-21 polypeptides and targeted constructs | |
| WO2022226054A3 (en) | Antigen presenting polypeptide complexes bearing tgf-beta and methods of use thereof | |
| MX2024002390A (es) | Metodos para generar celulas inmunitarias primarias. | |
| MX2021010533A (es) | Receptores de linfocitos t y metodos de uso de estos. | |
| MX2024015534A (es) | Composiciones y metodos para reducir mhc de clase i en una celula | |
| WO2021072127A3 (en) | Engineered trimeric cd70 proteins and uses thereof | |
| MX2022015788A (es) | Metodos y composiciones para editar el sitio de b2m en celulas b. | |
| MX2025009917A (es) | Metodos para generar celulas inmunitarias primarias | |
| WO2009062260A8 (en) | Therapy for multiple sclerosis | |
| PH12021551619A1 (en) | Car t cell methods and constructs | |
| MX2022014134A (es) | Tratamiento conjunto con pbmc modificadas y un inmunoconjugado. |